Iomeron

Iomeprol, the active ingredient in Iomeron, is an iodinated contrast media presented as a sterile solution for injection for intraarterial, intraarticular, and intravenous use. It enhances radiographic visualization of vascular and tissue structures during diagnostic imaging procedures such as angiography, computed tomography, arthrography, and myelography.

GNH USA supplies Iomeron as a licensed, GDP‑compliant international pharmaceutical product to hospitals, imaging centres and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support global distribution. Customers benefit from reliable supply chains and responsive technical support.

Iomeron (iomeprol) is an iodinated contrast media used to improve radiographic visualization in several diagnostic imaging pathways. - Angiography: Improves visualization of blood vessels during catheter‑based imaging. - CT imaging: Increases contrast between tissues, allowing detailed cross‑sectional images. - Arthrography: Enhances joint space delineation for assessment of cartilage and structures. - Myelography: Provides clear contrast of the spinal canal and nerve roots.

Iomeron may be associated with a range of adverse reactions, ranging from mild and transient to severe.

Common Side Effects: - Warmth or flushing sensation at the injection site, usually lasting a few seconds. - Metallic or salty taste in the mouth that resolves shortly after the procedure. - Nausea, occasional mild vomiting, and transient abdominal discomfort. - Headache or mild dizziness occurring within minutes of administration.

Serious or Rare Side Effects: - Severe allergic reactions, including anaphylaxis, with symptoms such as rash, bronchospasm, and hypotension. - Acute kidney injury, particularly in patients with pre‑existing renal impairment or dehydration. - Thyroid dysfunction, including hyper‑ or hypothyroidism, due to the high iodine load. - Cardiovascular collapse or profound hypotension requiring emergency intervention.

When using Iomeron, clinicians should observe several precautionary measures to minimise risk and ensure optimal imaging outcomes. - Renal function assessment: evaluate serum creatinine and eGFR before administration. - Allergy history: screen for prior reactions to iodinated contrast or iodine‑containing substances. - Thyroid disease: consider risk of iodine‑induced thyroid dysfunction in patients with known thyroid disorders. - Metformin therapy: temporarily discontinue metformin in patients with reduced renal function to avoid lactic acidosis. - Pediatric use: adjust dose carefully and monitor for adverse reactions in children. - Store at ambient temperature: keep the solution in its original packaging, protect from light and moisture, and do not freeze.

Iomeron can interact with certain medications, influencing safety or efficacy.

Major Interactions (Avoid): - Iodine‑containing thyroid hormones (e.g., levothyroxine): may cause excess iodine load and thyroid dysfunction. - Metformin in patients with impaired renal function: risk of lactic acidosis after contrast exposure. - Nephrotoxic agents (e.g., aminoglycosides, amphotericin B): increase likelihood of contrast‑induced nephropathy.

Moderate Interactions (Monitor Closely): - Diuretics and ACE inhibitors: may affect renal perfusion and heighten kidney injury risk. - NSAIDs: can reduce renal blood flow, augmenting nephrotoxic potential. - Beta‑blockers and calcium channel blockers: may mask signs of contrast‑related hypotension. - Oral iodinated contrast agents: cumulative iodine exposure may exacerbate thyroid effects.